266 related articles for article (PubMed ID: 21340513)
1. Updates in cytogenetics and molecular markers in MDS.
Tiu RV; Visconte V; Traina F; Schwandt A; Maciejewski JP
Curr Hematol Malig Rep; 2011 Jun; 6(2):126-35. PubMed ID: 21340513
[TBL] [Abstract][Full Text] [Related]
2. Combining metaphase cytogenetics with single nucleotide polymorphism arrays can improve the diagnostic yield and identify prognosis more precisely in myelodysplastic syndromes.
Qin Y; Zhang H; Feng L; Wei H; Wu Y; Jiang C; Xu Z; Zhu H; Liu T
Ann Med; 2022 Dec; 54(1):2627-2636. PubMed ID: 36148999
[TBL] [Abstract][Full Text] [Related]
3. Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide.
Sugimoto Y; Sekeres MA; Makishima H; Traina F; Visconte V; Jankowska A; Jerez A; Szpurka H; O'Keefe CL; Guinta K; Afable M; Tiu R; McGraw KL; List AF; Maciejewski J
J Hematol Oncol; 2012 Mar; 5():4. PubMed ID: 22390313
[TBL] [Abstract][Full Text] [Related]
4. [Progress of cytogenetic detection in myelodysplastic syndromes].
Zhou QB; Hu XM; Liu -; Ma R
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Dec; 19(6):1536-40. PubMed ID: 22169320
[TBL] [Abstract][Full Text] [Related]
5. [Diagnosis and prognosis in myelodysplastic syndromes. The impact of cytogenetics].
Mecucci C
Recenti Prog Med; 2014 Mar; 105(3):110-4. PubMed ID: 24675452
[TBL] [Abstract][Full Text] [Related]
6. Recurrent Cytogenetic Abnormalities in Myelodysplastic Syndromes.
Wall M
Methods Mol Biol; 2017; 1541():209-222. PubMed ID: 27910026
[TBL] [Abstract][Full Text] [Related]
7. Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies.
Tiu RV; Gondek LP; O'Keefe CL; Elson P; Huh J; Mohamedali A; Kulasekararaj A; Advani AS; Paquette R; List AF; Sekeres MA; McDevitt MA; Mufti GJ; Maciejewski JP
Blood; 2011 Apr; 117(17):4552-60. PubMed ID: 21285439
[TBL] [Abstract][Full Text] [Related]
8. Single-nucleotide polymorphism array (SNP-A) improves the identification of chromosomal abnormalities by metaphase cytogenetics in myelodysplastic syndrome.
da Silva FB; Machado-Neto JA; Bertini VHLL; Velloso EDRP; Ratis CA; Calado RT; Simões BP; Rego EM; Traina F
J Clin Pathol; 2017 May; 70(5):435-442. PubMed ID: 27836923
[TBL] [Abstract][Full Text] [Related]
9. Cytogenetic place in managing myelodysplastic syndromes: an update by the Groupe francophone de cytogénétique hématologique (GFCH).
Eclache V; Lafage-Pochitaloff M; Lefebvre C; Penther D; Raynaud S; Tigaud I
Ann Biol Clin (Paris); 2016 Oct; 74(5):525-534. PubMed ID: 27546835
[TBL] [Abstract][Full Text] [Related]
10. Combined comparative genomic hybridization and single-nucleotide polymorphism array detects cryptic chromosomal lesions in both myelodysplastic syndromes and cytopenias of undetermined significance.
Evans AG; Ahmad A; Burack WR; Iqbal MA
Mod Pathol; 2016 Oct; 29(10):1183-99. PubMed ID: 27389314
[TBL] [Abstract][Full Text] [Related]
11. Significance of genome-wide analysis of copy number alterations and UPD in myelodysplastic syndromes using combined CGH - SNP arrays.
Ahmad A; Iqbal MA
Curr Med Chem; 2012; 19(22):3739-47. PubMed ID: 22680919
[TBL] [Abstract][Full Text] [Related]
12. The need for additional genetic markers for myelodysplastic syndrome stratification: what does the future hold for prognostication?
Otrock ZK; Tiu RV; Maciejewski JP; Sekeres MA
Expert Rev Hematol; 2013 Feb; 6(1):59-68. PubMed ID: 23373781
[TBL] [Abstract][Full Text] [Related]
13. Mutations of myelodysplastic syndromes (MDS): An update.
Ganguly BB; Kadam NN
Mutat Res Rev Mutat Res; 2016; 769():47-62. PubMed ID: 27543316
[TBL] [Abstract][Full Text] [Related]
14. Myelodysplastic syndromes with del(5q): indications and strategies for cytogenetic testing.
Haferlach C; Bacher U; Tiu R; Maciejewski JP; List A
Cancer Genet Cytogenet; 2008 Dec; 187(2):101-11. PubMed ID: 19027491
[TBL] [Abstract][Full Text] [Related]
15. Genetics of myelodysplastic syndromes: new insights.
Graubert T; Walter MJ
Hematology Am Soc Hematol Educ Program; 2011; 2011():543-9. PubMed ID: 22160087
[TBL] [Abstract][Full Text] [Related]
16. [Progress of Clinical Application of SNP-A to MDS--Review].
Chi K; Jing XY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Aug; 26(4):1244-1247. PubMed ID: 30111439
[TBL] [Abstract][Full Text] [Related]
17. FISH and SNP-A karyotyping in myelodysplastic syndromes: improving cytogenetic detection of del(5q), monosomy 7, del(7q), trisomy 8 and del(20q).
Makishima H; Rataul M; Gondek LP; Huh J; Cook JR; Theil KS; Sekeres MA; Kuczkowski E; O'Keefe C; Maciejewski JP
Leuk Res; 2010 Apr; 34(4):447-53. PubMed ID: 19758696
[TBL] [Abstract][Full Text] [Related]
18. [Recent advances of molecular mechanisms influencing prognosis of myelodysplastic syndrome - review].
Guo J; Chang CK; Li X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Aug; 20(4):1020-4. PubMed ID: 22931676
[TBL] [Abstract][Full Text] [Related]
19. Genetic abnormalities and pathophysiology of MDS.
Hosono N
Int J Clin Oncol; 2019 Aug; 24(8):885-892. PubMed ID: 31093808
[TBL] [Abstract][Full Text] [Related]
20. High-resolution genomic arrays facilitate detection of novel cryptic chromosomal lesions in myelodysplastic syndromes.
O'Keefe CL; Tiu R; Gondek LP; Powers J; Theil KS; Kalaycio M; Lichtin A; Sekeres MA; Maciejewski JP
Exp Hematol; 2007 Feb; 35(2):240-51. PubMed ID: 17258073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
